Global Peptide and Oligonucleotide Drugs Market Research Report 2026

1 Peptide and Oligonucleotide Drugs Market Overview
1.1 Product Definition
1.2 Peptide and Oligonucleotide Drugs by Type
1.2.1 Global Peptide and Oligonucleotide Drugs Market Value by Type: 2025 vs 2032
1.2.2 Oligonucleotide Drugs
1.2.3 Peptide Drugs
1.3 Peptide and Oligonucleotide Drugs by Application
1.3.1 Global Peptide and Oligonucleotide Drugs Market Value by Application: 2025 vs 2032
1.3.2 Immunomodulatory Drugs
1.3.3 Digestive system Drugs
1.3.4 Bone and Connective Tissue Types
1.3.5 Oncology Drugs
1.3.6 Other
1.4 Global Peptide and Oligonucleotide Drugs Market Size Estimates and Forecasts
1.4.1 Global Peptide and Oligonucleotide Drugs Revenue 2021–2032
1.4.2 Global Peptide and Oligonucleotide Drugs Sales 2021–2032
1.4.3 Global Peptide and Oligonucleotide Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Peptide and Oligonucleotide Drugs Market Competition by Manufacturers
2.1 Global Peptide and Oligonucleotide Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Peptide and Oligonucleotide Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Peptide and Oligonucleotide Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Peptide and Oligonucleotide Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Peptide and Oligonucleotide Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Peptide and Oligonucleotide Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Peptide and Oligonucleotide Drugs, Date of Entry into the Industry
2.8 Global Peptide and Oligonucleotide Drugs Market Competitive Situation and Trends
2.8.1 Global Peptide and Oligonucleotide Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Peptide and Oligonucleotide Drugs Players Market Share by Revenue
2.8.3 Global Peptide and Oligonucleotide Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Peptide and Oligonucleotide Drugs Market Scenario by Region
3.1 Global Peptide and Oligonucleotide Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Peptide and Oligonucleotide Drugs Sales by Region: 2021–2032
3.2.1 Global Peptide and Oligonucleotide Drugs Sales by Region: 2021–2026
3.2.2 Global Peptide and Oligonucleotide Drugs Sales by Region: 2027–2032
3.3 Global Peptide and Oligonucleotide Drugs Revenue by Region: 2021–2032
3.3.1 Global Peptide and Oligonucleotide Drugs Revenue by Region: 2021–2026
3.3.2 Global Peptide and Oligonucleotide Drugs Revenue by Region: 2027–2032
3.4 North America Peptide and Oligonucleotide Drugs Market Facts & Figures by Country
3.4.1 North America Peptide and Oligonucleotide Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Peptide and Oligonucleotide Drugs Sales by Country (2021–2032)
3.4.3 North America Peptide and Oligonucleotide Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Peptide and Oligonucleotide Drugs Market Facts & Figures by Country
3.5.1 Europe Peptide and Oligonucleotide Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Peptide and Oligonucleotide Drugs Sales by Country (2021–2032)
3.5.3 Europe Peptide and Oligonucleotide Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Peptide and Oligonucleotide Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Peptide and Oligonucleotide Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Peptide and Oligonucleotide Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Peptide and Oligonucleotide Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Peptide and Oligonucleotide Drugs Market Facts & Figures by Country
3.7.1 Latin America Peptide and Oligonucleotide Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Peptide and Oligonucleotide Drugs Sales by Country (2021–2032)
3.7.3 Latin America Peptide and Oligonucleotide Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Peptide and Oligonucleotide Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Peptide and Oligonucleotide Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Peptide and Oligonucleotide Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Peptide and Oligonucleotide Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Peptide and Oligonucleotide Drugs Sales by Type (2021–2032)
4.1.1 Global Peptide and Oligonucleotide Drugs Sales by Type (2021–2026)
4.1.2 Global Peptide and Oligonucleotide Drugs Sales by Type (2027–2032)
4.1.3 Global Peptide and Oligonucleotide Drugs Sales Market Share by Type (2021–2032)
4.2 Global Peptide and Oligonucleotide Drugs Revenue by Type (2021–2032)
4.2.1 Global Peptide and Oligonucleotide Drugs Revenue by Type (2021–2026)
4.2.2 Global Peptide and Oligonucleotide Drugs Revenue by Type (2027–2032)
4.2.3 Global Peptide and Oligonucleotide Drugs Revenue Market Share by Type (2021–2032)
4.3 Global Peptide and Oligonucleotide Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global Peptide and Oligonucleotide Drugs Sales by Application (2021–2032)
5.1.1 Global Peptide and Oligonucleotide Drugs Sales by Application (2021–2026)
5.1.2 Global Peptide and Oligonucleotide Drugs Sales by Application (2027–2032)
5.1.3 Global Peptide and Oligonucleotide Drugs Sales Market Share by Application (2021–2032)
5.2 Global Peptide and Oligonucleotide Drugs Revenue by Application (2021–2032)
5.2.1 Global Peptide and Oligonucleotide Drugs Revenue by Application (2021–2026)
5.2.2 Global Peptide and Oligonucleotide Drugs Revenue by Application (2027–2032)
5.2.3 Global Peptide and Oligonucleotide Drugs Revenue Market Share by Application (2021–2032)
5.3 Global Peptide and Oligonucleotide Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Novartis Peptide and Oligonucleotide Drugs Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Ionis
6.2.1 Ionis Company Information
6.2.2 Ionis Description and Business Overview
6.2.3 Ionis Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Ionis Peptide and Oligonucleotide Drugs Product Portfolio
6.2.5 Ionis Recent Developments/Updates
6.3 Nippon Shinyaku
6.3.1 Nippon Shinyaku Company Information
6.3.2 Nippon Shinyaku Description and Business Overview
6.3.3 Nippon Shinyaku Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Nippon Shinyaku Peptide and Oligonucleotide Drugs Product Portfolio
6.3.5 Nippon Shinyaku Recent Developments/Updates
6.4 Alnylam
6.4.1 Alnylam Company Information
6.4.2 Alnylam Description and Business Overview
6.4.3 Alnylam Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Alnylam Peptide and Oligonucleotide Drugs Product Portfolio
6.4.5 Alnylam Recent Developments/Updates
6.5 Sarepta Therapeutics
6.5.1 Sarepta Therapeutics Company Information
6.5.2 Sarepta Therapeutics Description and Business Overview
6.5.3 Sarepta Therapeutics Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Sarepta Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio
6.5.5 Sarepta Therapeutics Recent Developments/Updates
6.6 MiNA Therapeutics
6.6.1 MiNA Therapeutics Company Information
6.6.2 MiNA Therapeutics Description and Business Overview
6.6.3 MiNA Therapeutics Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 MiNA Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio
6.6.5 MiNA Therapeutics Recent Developments/Updates
6.7 BioNTech
6.7.1 BioNTech Company Information
6.7.2 BioNTech Description and Business Overview
6.7.3 BioNTech Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 BioNTech Peptide and Oligonucleotide Drugs Product Portfolio
6.7.5 BioNTech Recent Developments/Updates
6.8 Moderna
6.8.1 Moderna Company Information
6.8.2 Moderna Description and Business Overview
6.8.3 Moderna Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Moderna Peptide and Oligonucleotide Drugs Product Portfolio
6.8.5 Moderna Recent Developments/Updates
6.9 Merck Serono
6.9.1 Merck Serono Company Information
6.9.2 Merck Serono Description and Business Overview
6.9.3 Merck Serono Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Merck Serono Peptide and Oligonucleotide Drugs Product Portfolio
6.9.5 Merck Serono Recent Developments/Updates
6.10 Ferring Pharmaceuticals
6.10.1 Ferring Pharmaceuticals Company Information
6.10.2 Ferring Pharmaceuticals Description and Business Overview
6.10.3 Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio
6.10.5 Ferring Pharmaceuticals Recent Developments/Updates
6.11 Ipsen PHarma Biotech
6.11.1 Ipsen PHarma Biotech Company Information
6.11.2 Ipsen PHarma Biotech Description and Business Overview
6.11.3 Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Product Portfolio
6.11.5 Ipsen PHarma Biotech Recent Developments/Updates
6.12 Lilly
6.12.1 Lilly Company Information
6.12.2 Lilly Description and Business Overview
6.12.3 Lilly Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Lilly Peptide and Oligonucleotide Drugs Product Portfolio
6.12.5 Lilly Recent Developments/Updates
6.13 Asahi Kasei
6.13.1 Asahi Kasei Company Information
6.13.2 Asahi Kasei Description and Business Overview
6.13.3 Asahi Kasei Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Asahi Kasei Peptide and Oligonucleotide Drugs Product Portfolio
6.13.5 Asahi Kasei Recent Developments/Updates
6.14 AstraZeneca
6.14.1 AstraZeneca Company Information
6.14.2 AstraZeneca Description and Business Overview
6.14.3 AstraZeneca Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 AstraZeneca Peptide and Oligonucleotide Drugs Product Portfolio
6.14.5 AstraZeneca Recent Developments/Updates
6.15 SciClone Pharmaceuticals
6.15.1 SciClone Pharmaceuticals Company Information
6.15.2 SciClone Pharmaceuticals Description and Business Overview
6.15.3 SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio
6.15.5 SciClone Pharmaceuticals Recent Developments/Updates
6.16 Takeda
6.16.1 Takeda Company Information
6.16.2 Takeda Description and Business Overview
6.16.3 Takeda Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Takeda Peptide and Oligonucleotide Drugs Product Portfolio
6.16.5 Takeda Recent Developments/Updates
6.17 Roche
6.17.1 Roche Company Information
6.17.2 Roche Description and Business Overview
6.17.3 Roche Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Roche Peptide and Oligonucleotide Drugs Product Portfolio
6.17.5 Roche Recent Developments/Updates
6.18 Sanofi
6.18.1 Sanofi Company Information
6.18.2 Sanofi Description and Business Overview
6.18.3 Sanofi Peptide and Oligonucleotide Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Sanofi Peptide and Oligonucleotide Drugs Product Portfolio
6.18.5 Sanofi Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Peptide and Oligonucleotide Drugs Industry Chain Analysis
7.2 Peptide and Oligonucleotide Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Peptide and Oligonucleotide Drugs Production Mode & Process Analysis
7.4 Peptide and Oligonucleotide Drugs Sales and Marketing
7.4.1 Peptide and Oligonucleotide Drugs Sales Channels
7.4.2 Peptide and Oligonucleotide Drugs Distributors
7.5 Peptide and Oligonucleotide Drugs Customer Analysis
8 Peptide and Oligonucleotide Drugs Market Dynamics
8.1 Peptide and Oligonucleotide Drugs Industry Trends
8.2 Peptide and Oligonucleotide Drugs Market Drivers
8.3 Peptide and Oligonucleotide Drugs Market Challenges
8.4 Peptide and Oligonucleotide Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global Peptide and Oligonucleotide Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Peptide and Oligonucleotide Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Peptide and Oligonucleotide Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Peptide and Oligonucleotide Drugs Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Peptide and Oligonucleotide Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Peptide and Oligonucleotide Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Peptide and Oligonucleotide Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Peptide and Oligonucleotide Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Peptide and Oligonucleotide Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Peptide and Oligonucleotide Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Peptide and Oligonucleotide Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Peptide and Oligonucleotide Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Peptide and Oligonucleotide Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Peptide and Oligonucleotide Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Peptide and Oligonucleotide Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Peptide and Oligonucleotide Drugs Sales by Region (K Units), 2021–2026
Table 18. Global Peptide and Oligonucleotide Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Peptide and Oligonucleotide Drugs Sales by Region (K Units), 2027–2032
Table 20. Global Peptide and Oligonucleotide Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Peptide and Oligonucleotide Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Peptide and Oligonucleotide Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Peptide and Oligonucleotide Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Peptide and Oligonucleotide Drugs Sales by Country (K Units), 2021–2026
Table 27. North America Peptide and Oligonucleotide Drugs Sales by Country (K Units), 2027–2032
Table 28. North America Peptide and Oligonucleotide Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Peptide and Oligonucleotide Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Peptide and Oligonucleotide Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Peptide and Oligonucleotide Drugs Sales by Country (K Units), 2021–2026
Table 32. Europe Peptide and Oligonucleotide Drugs Sales by Country (K Units), 2027–2032
Table 33. Europe Peptide and Oligonucleotide Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Peptide and Oligonucleotide Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Peptide and Oligonucleotide Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Peptide and Oligonucleotide Drugs Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Peptide and Oligonucleotide Drugs Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Peptide and Oligonucleotide Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Peptide and Oligonucleotide Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Peptide and Oligonucleotide Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Peptide and Oligonucleotide Drugs Sales by Country (K Units), 2021–2026
Table 42. Latin America Peptide and Oligonucleotide Drugs Sales by Country (K Units), 2027–2032
Table 43. Latin America Peptide and Oligonucleotide Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Peptide and Oligonucleotide Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Peptide and Oligonucleotide Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Peptide and Oligonucleotide Drugs Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Peptide and Oligonucleotide Drugs Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Peptide and Oligonucleotide Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Peptide and Oligonucleotide Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Peptide and Oligonucleotide Drugs Sales (K Units) by Type (2021–2026)
Table 51. Global Peptide and Oligonucleotide Drugs Sales (K Units) by Type (2027–2032)
Table 52. Global Peptide and Oligonucleotide Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Peptide and Oligonucleotide Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Peptide and Oligonucleotide Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Peptide and Oligonucleotide Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Peptide and Oligonucleotide Drugs Price (US$/Unit) by Type (2021–2026)
Table 59. Global Peptide and Oligonucleotide Drugs Price (US$/Unit) by Type (2027–2032)
Table 60. Global Peptide and Oligonucleotide Drugs Sales (K Units) by Application (2021–2026)
Table 61. Global Peptide and Oligonucleotide Drugs Sales (K Units) by Application (2027–2032)
Table 62. Global Peptide and Oligonucleotide Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Peptide and Oligonucleotide Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Peptide and Oligonucleotide Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Peptide and Oligonucleotide Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Peptide and Oligonucleotide Drugs Price (US$/Unit) by Application (2021–2026)
Table 69. Global Peptide and Oligonucleotide Drugs Price (US$/Unit) by Application (2027–2032)
Table 70. Novartis Company Information
Table 71. Novartis Description and Business Overview
Table 72. Novartis Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Novartis Peptide and Oligonucleotide Drugs Product
Table 74. Novartis Recent Developments/Updates
Table 75. Ionis Company Information
Table 76. Ionis Description and Business Overview
Table 77. Ionis Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Ionis Peptide and Oligonucleotide Drugs Product
Table 79. Ionis Recent Developments/Updates
Table 80. Nippon Shinyaku Company Information
Table 81. Nippon Shinyaku Description and Business Overview
Table 82. Nippon Shinyaku Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Nippon Shinyaku Peptide and Oligonucleotide Drugs Product
Table 84. Nippon Shinyaku Recent Developments/Updates
Table 85. Alnylam Company Information
Table 86. Alnylam Description and Business Overview
Table 87. Alnylam Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Alnylam Peptide and Oligonucleotide Drugs Product
Table 89. Alnylam Recent Developments/Updates
Table 90. Sarepta Therapeutics Company Information
Table 91. Sarepta Therapeutics Description and Business Overview
Table 92. Sarepta Therapeutics Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Sarepta Therapeutics Peptide and Oligonucleotide Drugs Product
Table 94. Sarepta Therapeutics Recent Developments/Updates
Table 95. MiNA Therapeutics Company Information
Table 96. MiNA Therapeutics Description and Business Overview
Table 97. MiNA Therapeutics Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. MiNA Therapeutics Peptide and Oligonucleotide Drugs Product
Table 99. MiNA Therapeutics Recent Developments/Updates
Table 100. BioNTech Company Information
Table 101. BioNTech Description and Business Overview
Table 102. BioNTech Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. BioNTech Peptide and Oligonucleotide Drugs Product
Table 104. BioNTech Recent Developments/Updates
Table 105. Moderna Company Information
Table 106. Moderna Description and Business Overview
Table 107. Moderna Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Moderna Peptide and Oligonucleotide Drugs Product
Table 109. Moderna Recent Developments/Updates
Table 110. Merck Serono Company Information
Table 111. Merck Serono Description and Business Overview
Table 112. Merck Serono Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Merck Serono Peptide and Oligonucleotide Drugs Product
Table 114. Merck Serono Recent Developments/Updates
Table 115. Ferring Pharmaceuticals Company Information
Table 116. Ferring Pharmaceuticals Description and Business Overview
Table 117. Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Product
Table 119. Ferring Pharmaceuticals Recent Developments/Updates
Table 120. Ipsen PHarma Biotech Company Information
Table 121. Ipsen PHarma Biotech Description and Business Overview
Table 122. Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Product
Table 124. Ipsen PHarma Biotech Recent Developments/Updates
Table 125. Lilly Company Information
Table 126. Lilly Description and Business Overview
Table 127. Lilly Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Lilly Peptide and Oligonucleotide Drugs Product
Table 129. Lilly Recent Developments/Updates
Table 130. Asahi Kasei Company Information
Table 131. Asahi Kasei Description and Business Overview
Table 132. Asahi Kasei Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Asahi Kasei Peptide and Oligonucleotide Drugs Product
Table 134. Asahi Kasei Recent Developments/Updates
Table 135. AstraZeneca Company Information
Table 136. AstraZeneca Description and Business Overview
Table 137. AstraZeneca Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. AstraZeneca Peptide and Oligonucleotide Drugs Product
Table 139. AstraZeneca Recent Developments/Updates
Table 140. SciClone Pharmaceuticals Company Information
Table 141. SciClone Pharmaceuticals Description and Business Overview
Table 142. SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Product
Table 144. SciClone Pharmaceuticals Recent Developments/Updates
Table 145. Takeda Company Information
Table 146. Takeda Description and Business Overview
Table 147. Takeda Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 148. Takeda Peptide and Oligonucleotide Drugs Product
Table 149. Takeda Recent Developments/Updates
Table 150. Roche Company Information
Table 151. Roche Description and Business Overview
Table 152. Roche Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 153. Roche Peptide and Oligonucleotide Drugs Product
Table 154. Roche Recent Developments/Updates
Table 155. Sanofi Company Information
Table 156. Sanofi Description and Business Overview
Table 157. Sanofi Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 158. Sanofi Peptide and Oligonucleotide Drugs Product
Table 159. Sanofi Recent Developments/Updates
Table 160. Key Raw Materials Lists
Table 161. Raw Materials Key Suppliers Lists
Table 162. Peptide and Oligonucleotide Drugs Distributors List
Table 163. Peptide and Oligonucleotide Drugs Customers List
Table 164. Peptide and Oligonucleotide Drugs Market Trends
Table 165. Peptide and Oligonucleotide Drugs Market Drivers
Table 166. Peptide and Oligonucleotide Drugs Market Challenges
Table 167. Peptide and Oligonucleotide Drugs Market Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
Table 171. Authors List of This Report


List of Figures
Figure 1. Product Picture of Peptide and Oligonucleotide Drugs
Figure 2. Global Peptide and Oligonucleotide Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Peptide and Oligonucleotide Drugs Market Share by Type: 2025 & 2032
Figure 4. Oligonucleotide Drugs Product Picture
Figure 5. Peptide Drugs Product Picture
Figure 6. Global Peptide and Oligonucleotide Drugs Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Peptide and Oligonucleotide Drugs Market Share by Application: 2025 & 2032
Figure 8. Immunomodulatory Drugs
Figure 9. Digestive system Drugs
Figure 10. Bone and Connective Tissue Types
Figure 11. Oncology Drugs
Figure 12. Other
Figure 13. Global Peptide and Oligonucleotide Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Peptide and Oligonucleotide Drugs Market Size (US$ Million), 2021–2032
Figure 15. Global Peptide and Oligonucleotide Drugs Sales (K Units), 2021–2032
Figure 16. Global Peptide and Oligonucleotide Drugs Average Price (US$/Unit), 2021–2032
Figure 17. Peptide and Oligonucleotide Drugs Report Years Considered
Figure 18. Peptide and Oligonucleotide Drugs Sales Share by Manufacturers in 2025
Figure 19. Global Peptide and Oligonucleotide Drugs Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Peptide and Oligonucleotide Drugs Players: Market Share by Revenue in Peptide and Oligonucleotide Drugs in 2025
Figure 21. Peptide and Oligonucleotide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Peptide and Oligonucleotide Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021–2032)
Figure 24. North America Peptide and Oligonucleotide Drugs Revenue Market Share by Country (2021–2032)
Figure 25. United States Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021–2032)
Figure 28. Europe Peptide and Oligonucleotide Drugs Revenue Market Share by Country (2021–2032)
Figure 29. Germany Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Peptide and Oligonucleotide Drugs Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Peptide and Oligonucleotide Drugs Revenue Market Share by Region (2021–2032)
Figure 36. China Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021–2032)
Figure 44. Latin America Peptide and Oligonucleotide Drugs Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Peptide and Oligonucleotide Drugs Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Peptide and Oligonucleotide Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Peptide and Oligonucleotide Drugs by Type (2021–2032)
Figure 55. Global Revenue Market Share of Peptide and Oligonucleotide Drugs by Type (2021–2032)
Figure 56. Global Peptide and Oligonucleotide Drugs Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Peptide and Oligonucleotide Drugs by Application (2021–2032)
Figure 58. Global Revenue Market Share of Peptide and Oligonucleotide Drugs by Application (2021–2032)
Figure 59. Global Peptide and Oligonucleotide Drugs Price (US$/Unit) by Application (2021–2032)
Figure 60. Peptide and Oligonucleotide Drugs Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit